Epirubicin Injection

Supply TypeManufacturer, Exporter, Supplier, Retailer
Preferred Buyer Location All over the world

We are a prominent Supplier and Exporter of Epirubicin Injection. Epirubicin Injection is indicated for adjuvant therapy in women and different types of cancers. We make Epirubicin Injection available at reasonable and competitive prices. Epirubicin Injection is provided by us to pharmacies, nursing homes and medical practitioners.

View More Details

Send Enquiry

Product Details

Details

Generic Name	Epirubicin
Brand Name	Alrubicin Injection
Strength Available	10 MG., 50 MG., 100 MG. and 150 MG.
Name of Company	Alkem Laboratories Ltd.
Classification	Antitumor antibiotic
Mechanism of Action	Anthracycline derivative of doxorubicin. Intercalates into DNA, which results in inhibition of DNA synthesis and function. Inhibits topoisomerase II by forming a cleavable complex with topoisomerase II and DNA. Involved in oxidation/reductions by generating cytotoxic oxygen free radicals, which can cause single-and doubie-stranded DNA breaks
Mechanism of Resistance	Increased expression of the muitidrug-resistant gene with enhanced drug efflux. This results in decreased intracellular drug accumulation. Decreased expression of topoisomerase II. Mutation in topoisomerase II with decreased binding affinity to drug. Increased expression of glutathione and glutathione-associated enzymes.
Absorption	Not orally bioavailable.
Distribution	Rapid and extensive distribution to formed blood elements and to body tissues. Does not cross the blood-brain barrier. Epirubicin is extensively bound (about 80%) to plasma proteins. Peak plasma levels are achieved immediately.
Metabolism	Extensive metabolism by the liver microsomal P450 system. Both active (epirubicinol) and inactive metabolites are formed. Elimination is mainly through the hepatobiliary route. Renal clearance accounts for only 20% of drug elimination. The half-life is approximately 30-38 hours for the parent compound and 20-31 hours for the epirubicinol metabolite.
Indications & Usage	Breast cancer - FDA-approved as a component of adjuvant therapy in women with axillary node involvement following resection of primary breast cancer. Metastatic breast cancer Gastric cancer
Dosage Range	Usual dose is 100-120 mg/m² IV every 3 weeks. In heavily pretreated patients, consider start��ing at lower dose of 75-90 mg/m² IV every 3 weeks. Alternative schedule is 12-25 mg/m² IV on a weekly basis.
Drung Preparation	Preparation Avaiiable as a red solution in single-use vials of 50 mg/25 mL, and 200 mg/1oo mL for IV use.
Drung Interaction	Heparin - Epiribucin is incompatible with heparin as a precipitate will form. 5-FU, cyclophosphamide - Increased risk of myelosuppression when epirubicin is used in combination with 5-FU and cyclophosphamide. Cimetidine - Cimetidine decreases the AUC of epirubicin by 50% and should be discontinued upon initiation of epirubicin therapy.
Special Considerations	Use with caution in patients with abnormal liver function. Dose modification should be consi��dered in patients with liver dysfunction. Use with caution in patients with severe renal impairment. Dose should be reduced by at least 50% when serum creatinine> 5 mg/dL. Use with caution in elderly patients as they are at increased risk for developing host toxicity. Careful monitoring of drug administration is necessary to avoid extravasation. If extrava��sation is suspected, stop infusion immediately, withdraw fluid, elevate arm, and apply ice to site. In severe cases, consult plastic surgeon. Monitor cardiac function before (baseline) and periodically during therapy with either MUGA radionuclide scan or echocardiogram to assess LVEF. Risk of cardiotoxicity is higher in elderly patients > 70 years of age, in patients with prior history of hypertension or pre-existing heart disease, in patients previously treated with anthracyclines, or in patients with prior radiation therapy to the cihest. In patients with no prior history of anthracycline therapy, cumu��lative doses of 900 mg/m² are associated with increased risk for cardiotoxicity. Epirubicin may be administered on a weekly schedule to decrease the risk of cardiotoxicity. Monitor weekly CBC while on therapy. Use with caution in patients previously treated with irradiation as epirubicin may induce a radiation recall reaction. Patients may experience red-oranqe dis��¬coloration of urine for 24 hours after drug administration. Pregnancy category D. Breast-feeding should be avoided.
Toxicity	Myelosuppression. Dose-limiting toxicity with leukopenia more common than thrombocyto��penia. Nadir typically occurs at 6-14 days after treatment, with recovery of counts by day 21. Risk of myelosuppression is greater in elderly patients and in those previously treated with chemotherapy andlor radiation therapy. Mild nausea and vomiting. Occur less frequently than with doxorubicin. Mucositis and diarrhea. Dose-dependent, com��mon, and generally mild. Cardiotoxicity. Cardiac effects are similar to but iess severe than those of doxorubicin. Acute toxicity presents as rhythm or conduction disturbances, chest pain, and myopericarditis syndrome that typically occurs within the first 24-48 hours of drug administration. Transient and mostly asymptomatic, not dose-related. Chronic form of cardiotoxicity presents as a dilated cardiomyopathy with congestive heart failure. Risk of congestive heart failure increases significantly with cumulative doses > 900 mg/m². Continuous infusion and weekly schedules are associated with decreased risk of cardiotoxicity. Dexrazoxane may be helpful in preventing epirubicin-mediated cardiotoxicity. Alopecia. Onset within 10 days of initiation of therapy and regrowth of hair upon termination of treatment. Occurs much less commonly than with doxorubicin, being observed in only 25%��50% of patients. Potent vesicant. Extravasation can lead to tissue injury, inflammation, and chemical thrombophlebitis at the site of injection. Skin rash, flushing, hyperpigmentation of skin and nails, and photosensitivity. Radiation recall skin reaction can occur at previous sites of irradiation. Red-<>range discoloration of urine for 24 hours after drug administration.